

1 Comprehensive characterisation of molecular host- 2 pathogen interactions in influenza A virus-infected human 3 macrophages.

4 Authors

5 Sara Clohisey^{1,2}, Nicholas Parkinson^{1,2}, Bo Wang^{1,2}, Nicolas Bertin³, Helen Wise^{2,4}, Andru Tomoiu^{1,2},
6 FANTOM5 Consortium, Kim M. Summers⁵, Piero Carninci³, Alistair A. Forrest⁶, Yoshihide
7 Hayashizaki⁷, Paul Digard^{2¶}, David A. Hume^{4¶*}, J. Kenneth Baillie^{1¶*}.

8 Affiliations

9 ¹ Division of Genetics and Genomics, The Roslin Institute, University of Edinburgh, Edinburgh, United Kingdom

10 ² Division of Infection and Immunity, The Roslin Institute, University of Edinburgh, Edinburgh, United Kingdom

11 ³ RIKEN Center for Life Sciences Technologies, RIKEN Yokohama Campus, Yokohama 230-0045, Japan

12 ⁴ Clinical biochemistry, Clock Tower building, Western General Hospital, Edinburgh

13 ⁵ Mater Research Institute-University of Queensland, Translational Research Institute, Woolloongabba, Queensland

14 4102, Australia

15 ⁶ Harry Perkins Institute of Medical Research, 6 Verdun Street, Nedlands, Western Australia 6009, Australia.

16 ⁷ RIKEN Preventive Medicine and Diagnosis Innovation Program, 2F Main Research Building, 2-1 Hirosawa, Wako, Japan

17 ¶ Joint senior authors

18 * Joint corresponding authors

19

20


21

22

23 **Abstract**

24 Macrophages in the lung detect and respond to influenza A virus (IAV), determining the nature of
25 the immune response. Using terminal depth 5'-RNA sequencing (CAGE) we quantify
26 transcriptional activity of both host and pathogen over a 24-hour timecourse of IAV infection in
27 primary human monocyte-derived macrophages (MDM). We use a systems approach to describe
28 the transcriptional landscape of the host response to IAV contrasted with bacterial
29 lipopolysaccharide treated MDMs, observing a failure of IAV-treated MDMs to induce feedback
30 inhibitors of inflammation. Systematic comparison of host RNA sequences incorporated into viral
31 mRNA ("snatched") against a complete survey of background RNA in the host cell enables an
32 unbiased quantification of over-represented features of snatched host RNAs. We detect
33 preferential snatching of RNAs associated with snRNA transcription and demonstrate that cap-
34 snatching avoids transcripts encoding host ribosomal proteins, which are required by IAV for
35 replication.

36



37 **Graphical Abstract**

38 (A) Overview of bioinformatics pipeline. (B) Host gene expression reveals that human
 39 macrophages exposed to IAV exhibit sustained production of key inflammatory mediators and
 40 failure to induce expression of feedback inhibitors of inflammation. (C) Unbiased comparison with
 41 total background RNA expression demonstrates that IAV cap-snatching has a strong preference
 42 for, and aversion to, different groups of host transcripts.

43 Introduction

44 Influenza A virus (IAV) infection is responsible for an estimated 500,000 deaths and up to 5 million
45 severe respiratory illness cases each year (WHO). The virus infects the respiratory tract, binding to
46 and infiltrating the respiratory epithelium. The abundant macrophages of the airway and lung
47 interstitium detect and respond to the virus, determining both the nature and the magnitude of
48 the innate and acquired immune response (Cline, Beck and Bianchini, 2017) and contributing to
49 inflammatory cytokine production outside the lung in severe IAV (Short *et al.*, 2017).

50 Human monocyte-derived macrophages (MDM) can be infected with IAV, produce viral proteins
51 and release inflammatory cytokines in response to infection, thus they have been widely-studied
52 as an experimental model (Hoeve *et al.* 2012; Perrone *et al.* 2008; van Riel *et al.* 2011;
53 Monteerarat *et al.* 2010; Stasakova *et al.* 2005; Wang *et al.* 2012; Lee *et al.* 2009). In most
54 studies, infected macrophages have produced relatively small yields of infectious IAV, although
55 this has differed depending upon the virus strain and its virulence, and the cell population studied
56 (Perrone *et al.* 2008; Stasakova *et al.* 2005; Wang *et al.* 2012; Friesenhagen *et al.* 2012; Nicol and
57 Dutia 2014).

58 IAV is an RNA virus, containing 8 negative-sense segments that are transcribed and replicated in
59 the nucleus of the host cell. As an obligate intracellular parasite, IAV is reliant on host cellular
60 machinery for replication. To accomplish mRNA production, the IAV polymerase binds directly to
61 the 5' 7-methylguanylate cap of a nascent host RNA and cleaves it roughly 10-14 nucleotides
62 downstream. The snatched sequence, known as a "leader" sequence, is employed as a primer for
63 efficient transcription of the viral mRNA (Plotch *et al.*, 1981) and provides the cap to viral mRNA to
64 facilitate translation by host ribosomes. Previous large-scale studies of this process (Gu *et al.*,
65 2015; Koppstein *et al.*, 2015; Sikora *et al.*, 2017, 2014) have produced evidence that host-derived
66 RNA caps are frequently snatched from non-coding RNAs, particularly small nuclear RNAs

67 (snRNAs), due to their high abundance in infected cells. This has led to the conclusion that cap-
68 snatching is not a selective process – that is, that host mRNAs are snatched at random (Sikora *et*
69 *al.*, 2017; De Vlugt, Sikora and Pelchat, 2018). These previous RNA-Seq studies have detected
70 snatched leaders, but have been unable observe the complete pool of unsnatched sequences,
71 because of limited sequencing depth and resolution at the 5' end, both of which are necessary to
72 accurately quantify the background distribution of each host transcript. The CAGE RNA sequencing
73 method captures both host and virus-derived transcripts and, importantly, does not require a PCR
74 amplification step, thus eliminating PCR bias.

75 To overcome these limitations, we utilised cap analysis of gene expression (CAGE) to sequence
76 capped RNA from the primary MDMs of 4 human donors *in vitro* at 4 time points over the course
77 of a 24 hour, productive infection with IAV. This allows us to observe the transcriptional response
78 to IAV infection over time in unprecedented molecular detail. This work was carried out as part of
79 the FANTOM5 consortium. Data are accessible through the FANTOM5 ZENBU browser
80 (<http://fantom.gsc.riken.jp/zenbu/>) and the FANTOM5 Table Extraction Tool
81 (<http://fantom.gsc.riken.jp/5/tet/>).

82 We employ a systems approach to identify key features of transcription during IAV infection in
83 MDMs. We previously used CAGE to quantify, transcript expression, promoter and enhancer
84 activity in human MDM and produced a detailed time course profiling their response to bacterial
85 lipopolysaccharide (LPS) (Baillie *et al.*, 2017). As in our previous work, we use the principle of
86 coexpression to identify key biological processes (Forrest *et al.*, 2014; Baillie *et al.*, 2016), and
87 compare the response of MDMs to both IAV and LPS, revealing IAV-specific features of the host
88 response.

89 By comparing the sequences of the snatched population to the sequences of the total capped RNA
90 background, we have identified nucleotide sequence motifs associated with viral cap snatching
91 and, for the first time, motifs present in the background host mRNA population that are not

92 snatched. Furthermore, we have assigned transcript identity to leader sequences and observed
93 potential preferential snatching of transcripts encoding spliceosome components and avoidance
94 of transcripts encoding host ribosomes.

95 **Results**

96 **Human MDMs support productive infection with IAV**

97 After infection of MDMs from four different donors with influenza A/Udorn/72 (H3N2; hereafter,
98 IAV) at a multiplicity of infection (MOI) of 5 (Figure S 1 A), some cells were positive for viral antigen
99 (IAV nucleoprotein) by immunofluorescence after 2 hours and the large majority after 7 hours.
100 This suggested that viral mRNA molecules were being transcribed and translated (Figure S 1 B).
101 RNA libraries were prepared from cells 0, 2, 7, and 24 hours post-infection and from two
102 uninfected-infected samples at 0 and 24 hours. Libraries were sequenced using HeliScope CAGE
103 as previously described (Forrest *et al.*, 2014; Kanamori-Katayama *et al.*, 2011). MDMs were
104 exposed to IAV for 1 hour before the culture medium was replaced with fresh medium lacking IAV
105 therefore the 0 hours post-IAV time point refers to cells harvested after the initial IAV exposure
106 and immediately prior to medium replacement. We confirmed a previous report (Hoeve *et al.*,
107 2012) that IAV-infected MDM cells released infectious virus (Figure S 1 C), albeit at low levels
108 compared to published results for A549 epithelial cells and with little evidence of cell death up to
109 7 hours (Figure S 1 D). Despite producing relatively little infectious virus, the majority of the IAV-
110 infected MDMs were lost after 24 hours.

111 **Network analysis of the response to influenza virus infection in MDM**

112 RNA libraries were prepared from similarly infected cells at 0, 2, 7, and 24 hours post-infection
113 and from two uninfected samples at 0 and 24 hours. Libraries were sequenced using HeliScope
114 CAGE as previously described (Forrest *et al.*, 2014; Kanamori-Katayama *et al.*, 2011). Note that
115 MDMs were exposed to IAV for 1 hour before the culture medium was replaced with fresh


116 medium lacking virus; therefore the 0 hours post-infection time point refers to cells harvested
117 after the initial IAV exposure and immediately prior to medium replacement. In addition,
118 expression profiles of the MDM at 24 hours likely reflect the remaining survivors of the IAV
119 infection, since dead cells were detached from the plates and were thus not lysed for RNA
120 extraction.

121 **Network analysis of the response to IAV virus infection in MDM**

122 Temporal changes in host cell transcription are likely to occur both in recognition of viral infection
123 and as a consequence of viral lifecycle progression. This study gave us the opportunity to observe
124 changes in transcription at 4 time points over 24 hours of IAV infection. We utilised the network
125 analytical tool, Graphia (Freeman *et al.*, 2007), to identify sets of co-regulated transcripts in the
126 MDM response to IAV (Table S 1). For simplicity, we restricted the analysis to the dominant (most
127 frequently used) promoters (p1) and used averaged data from the 4 donors. We have
128 summarised the GO term enrichment and pathway enrichment in the 10 largest clusters using
129 GATHER (Chang and Nevins, 2006) (Table S 2) and Enrichr (Chen *et al.*, 2013; Kuleshov *et al.*,
130 2016) (Table S 3) respectively.

131 Figure 1 A shows the sample-to-sample correlation graph for each of the averaged data sets.
132 Although there was a global alteration in gene expression that progressed with time, the profile at
133 7 hours remained correlated with the profiles in uninfected cells at both early and late time
134 points. This suggests that the virus did not cause a selective, or global, loss of expression of host-
135 related genes. In keeping with that conclusion, the largest cluster, Cluster 1, contained more than
136 4,500 genes (Figure 1 B) whose shared pattern was continuous induction across the time course
137 with particularly high expression at 24 hours. This cluster contained genes encoding the
138 interferon-responsive transcription factors, *IRF1, 2, 4, 7, 8, and 9* and numerous known interferon-
139 responsive antiviral effector genes (e.g. *APOBEC3G, RSAD2, DDX58, ISG15, MX1, OAS1, TRIM25*).

140 Cluster 2, at less than half the size, is the near-reciprocal cluster to Cluster 1 as it contained genes
 141 that were progressively downregulated by IAV up to 7 hours post infection. A prominent feature
 142 of the GO annotation and pathway analysis of this cluster is protein synthesis, secretion and
 143



144
 145 **Figure 1. Network analysis of the co-expressed genes during IAV infection in MDMs demonstrates their**
 146 **rapid response.**

147 (A) Sample-to-sample network. A correlation coefficient of ≥ 0.7 was used to include all samples in the network.
 148 Analysis was restricted to the dominant promoters (p1) and data were averaged across the 4 donors. Blue –
 149 uninfected; pink – infected; darker colours show later time points. (B) Gene-to-gene correlation profile of transcripts.
 150 Network analysis identified the sets of co-regulated transcripts in the MDM response to IAV. Analysis was restricted
 151 to the dominant promoters (p1) and data were averaged across the 4 donors. Lines represent connections at Pearson
 152 correlation coefficient ≥ 0.94 and spheres represent genes (promoters). The clustering procedure used a relatively
 153 coarse Markov clustering algorithm of 1.7 to avoid excessive cluster fragmentation. The four largest clusters, along
 154 with their average expression profiles, are shown. Y axis in the expression profiles shows the expression level in tags

155 per million (TPM). (C-F) Abundance of transcripts for IL1B (C) EGR1 (D), TNF α (E) and CXCL2 (F) at the indicated time
156 points. y-axis shows expression in tags per million (TPM). (G) Differential gene expression analysis comparing
157 expression of transcripts in LPS- treated and IAV- treated monocyte derived MDMs. Transcripts with a relative log
158 fold change ($\log_2FC \geq 2$ and a $-\log_{10}(FDR) \geq 3$ are shown in red (higher in LPS treated) and blue (higher in IAV
159 infection). Genes with greatest difference in expression are labelled. Genes referenced in the text are shown in black.
160 (H) Comparison of the temporal response of genes between IAV- and LPS- treated MDMs. Expression (TPM) of
161 selected genes in LPS- treated (red) and IAV- infected (blue) human MDMs at 0, 2, 7, and 24 hours post treatment is
162 shown in tags per million (TPM). Solid lines show the mean expression of all donors (n = 3 for LPS, n = 4 for IAV).
163 Filled-in area shows standard deviation between donors.

164
165 intracellular transport (Table S 2, S 3), exemplified by multiple Golgi-associated genes (e.g.
166 *GOLGA2*, *GOLPH3*, *GGA3*), components of the coatamer complex (*COPA*, *COPG*) and secretory
167 components.
168 Clusters 3 and 4 had similar profiles to each other, differing only at the late time point of 24 hours,
169 and between them contained a set of rapidly-induced genes, including interferons *IFNB1*, *IFNA1*,
170 *IFNA2*, *IFNA8*, *IFNA14*, *IFNE* and further known IFN-regulated targets such as *IFI6*, *IFIT2*,
171 *IFITM3*, *IRG1*, *GBP1* and *MNDA*. The enrichment of these clusters also highlights induction of
172 genes involved in protein synthesis, including 46 ribosomal protein subunit genes and those
173 associated with the mitochondria, oxidative phosphorylation and ATP synthesis.

174 We observed that the response of MDMs to viral infection was immediate. IL1B was rapidly and
175 strongly induced by IAV at 0 hours (effectively 1 hour post virus addition) and peaked at 2 hours
176 (3 hours post virus addition) (Figure 1 C). Other early response genes that were detected early
177 after IAV exposure included those encoding immediate early transcription factors such as EGR1,
178 the proinflammatory cytokine TNF α and the neutrophil chemoattractant CXCL2 (Figure 1 D-F).

179 **Comparative analysis of the response of MDMs to treatment with IAV and with LPS**

180 The response of MDMs to IAV and LPS was compared at equivalent time points, uncovering some
181 common transcripts that were expressed in both treatments (Figure 1 H, top row). Transcripts

182 induced specifically by LPS but not by IAV were revealed by differential expression analysis (Figure
183 1 G, Table S 4) and included classical inflammatory cytokines IL12B (although not IL12A) and IL6,
184 and the feedback regulator of inflammation, IL10 (Figure 1 H, central row; Figure S 2 A, B).
185 Conversely, induction of genes associated with interferon signalling was more substantial and
186 prolonged in IAV-treated MDM than those treated with LPS. IAV induced *IFNB1* mRNA some 10-
187 fold more than observed in response to LPS in MDM, and sustained this expression throughout
188 the time course (Figure 1 H, bottom row). IAV also induced multiple IFNA genes (*IFNA1*, *A2*, *A8*,
189 *A14*, *A22*, Figure S 2 C-E) and the type III interferon genes, *IFNL1* (aka IL28A) and *IFNL2* (aka *IL29*),
190 which were not induced at all by LPS (Figure 1 H, bottom row; and Figure S 2 F).

191 **Transcriptional activity of IAV in human MDMs**

192 IAV mRNAs contain a conserved 12-base long 5'-adjacent non-coding region present in all 8
193 segments ('AGCAAAAGCAGG') derived from template-dependent transcription of the viral
194 promoter (De Vlugt, Sikora and Pelchat, 2018). Possession of this sequence was therefore used to
195 identify viral transcripts. Similar to results seen elsewhere (Gu *et al.*, 2015; Koppstein *et al.*, 2015;
196 Sikora *et al.*, 2014), the A at the 5' end of the promoter was not always present and thus
197 sequences which contained the 11 nucleotide sequence 'GCAAAAGCAGG', referred to
198 subsequently as the IAV promoter, were brought forward for analysis. The IAV promoter is
199 present in all 8 viral mRNA segments and follows the host-derived leader sequence (Figure 2 A).
200 Overall, the relative proportion of IAV mRNA arising from each viral segment was remarkably
201 consistent across the 4 donors at each time point, demonstrating the coordinated nature of
202 transcription by IAV (Figure S 3 A). Published studies of A549 cells reported that, within 8 hours
203 post-exposure, >50% of total cellular mRNA was viral (Bercovich-Kinori *et al.*, 2016). In contrast, in
204 the infected MDM capped IAV RNA constituted a relatively small proportion (4 -11%) of total
205 capped RNA in the cell even at the peak of viral replication (Figure S 3 B). The relative proportion
206 of IAV mRNA arising from each viral segment was remarkably consistent across the 4 donors at

207 each time point (Figure S 3 C) compatible with the understanding that transcription of each
208 segment is a highly controlled process (McCauley and Mahy, 1983). The relative proportions of the
209 viral transcripts encoding the polymerase segments (1, 2, 3, encoding PB2, PB1, and PA
210 respectively) peaked at the 0 hour post-infection time point (after 1 hour incubation with IAV),
211 together with the detectable induction of host response genes observed above. Relative
212 expression of segment 8 (NS1/NS2) was highest at 2 hours. The late structural segment
213 transcripts (4, 6, 7, encoding HA, NA and M1/M2 respectively) peaked at 7 hours, towards the end
214 of the expected 6-8 hour viral life cycle. By 24 hours, the pattern was less defined, which may be a
215 consequence of mRNA decay or potential reinfection by the virus. In addition, reads plausibly
216 corresponding to the known mRNA3 splice variant transcript from segment 7 which utilises a
217 splice donor site at the 3'-boundary of the conserved promoter sequence (Lamb, Lai and Choppin,
218 1981) were also seen (Figure S 3 D). Similar sequences that potentially represent alternative splice
219 variant mRNAs were observed, most abundantly from segments 5 and 6 (Figure S 3 D, Table S 5). It
220 is unknown if these can be translated.

221 **Characterisation of host leader sequences incorporated into viral capped RNA**

222 We identified 4,575,918 unique leader sequences, heterogeneous in both sequence and length,
223 snatched from the host and incorporated into viral mRNA. Of these leader sequences, 18.8%
224 (859,789) appeared more than once and 1.5% (69,443) appeared ten times or more across all
225 samples. This 1.5% of the most frequently occurring accounted for 53.6% of the total number of
226 snatched leaders. Thus, at least two populations of snatched sequences exist: those that were
227 heavily snatched as they occur multiple times, and those that were seemingly randomly snatched
228 as they appear only once. Most (74%) of the leader sequences were between 10 and 14
229 nucleotides long (Figure 2 B). Contrary to previous reports (Koppstein *et al.*, 2015; Sikora *et al.*,
230 2017), we observed no difference in leader lengths among different viral segments.


231 We sought to determine whether there was over-representation of particular sequences, host
232 transcripts, or biological pathways among the total population of leader sequences. In order to
233 eliminate the risk of bias due to the different rates of successful mapping for sequences of
234 different lengths, we restricted our analysis to the first 10 bases of every CAGE tag (10mers)
235 meeting the abundance threshold of 1,000 tags across all examined samples in the dataset,
236 including both IAV and host sequences. The number of times a 10mer was followed by the IAV
237 promoter, i.e. incorporated into viral mRNA (“snatched”), was compared to the number of times a
238 10mer was not followed by an IAV promoter (“unsnatched”) using Fisher’s Exact test (FDR <0.05)
239 at each time point (see Methods). We uncovered patterns of significant over- and under-
240 representation for specific 10mers.

241 **Enrichment of specific RNA motifs in the snatched and unsnatched sequence populations**

242 It is not known if the cap-snatching mechanism targets specific nucleic acid sequences. However,
243 leader sequences are known to commonly have ‘GCA’ at the interface between the host sequence
244 and the IAV promoter (Rao, Yuan and Krug, 2003; Geerts-Dimitriadou, Goldbach and Kormelink,
245 2011) partially as a consequence of the “prime and realign” mechanism of IAV mRNA transcription
246 (Beaton and Krug, 1981; Geerts-Dimitriadou *et al.*, 2011; Koppstein *et al.*, 2015). More recently,
247 an ‘AG’ at the 5’ end of the leader sequence has also been shown to be prevalent in snatched
248 sequences (Gu *et al.*, 2015).

249 Our analysis of 10mers enables a statistically powerful comparison of snatched and unsnatched
250 sequences in which the position of sequence motifs can be compared without reference to
251 distance from the 5’ or 3’ ends. We used Pysster (Budach and Marsico, 2018) to train
252 convolutional neural networks using the sequence data to explore sequence and positional
253 features for pools of highly-significantly over-represented snatched and unsnatched 10mers (0.3
254 \geq OR \geq 3, $-\log(\text{FDR} < 10)$). This stringency was introduced to eliminate potential noise.
255 Optimisation experiments indicated that a kernel (sequence motif) length of 4 had relatively

256 consistent recall and high precision for this dataset (Figure S 4). The snatched 10mers showed an
 257 enrichment of two motifs, A[G/C][T/A][C/G] and the similar sequence AGNN, both beginning at
 258 the first base (position 0) (Figure 2 C). These motifs were most apparent 2 hours post infection,
 259 coinciding with levels of high transcription by the virus and are consistent with previous reports of
 260 an 'AG' preference at the 5' end of the leader (Gu *et al.*, 2015).
 261 The unsnatched 10mers also showed an enrichment of two distinct motifs, CTAG and
 262 [T/C][A/T][T/G/A]A, most evident at 7 hours post infection (Figure 2 D). While the CTAG motif was
 263 unsnatched primarily when it began in the first position (position 0), there was also an association
 264 between this motif at any position in the 10mer and unsnatched status. Similarly, the
 265
 266



267

268 **Figure 2. Motifs associated with snatched and unsnatched leader sequences**

269 (A) Schematic showing the structure of the capped 5' end of IAV mRNAs. (B) Length of leader sequences across

270 segments. Segments are coloured as shown in the legend. (C, D) The first ten nucleotides of each CAGE tag were

271 extracted and the abundance of each sequence associated with IAV was compared to the background abundance by
272 Fisher's Exact test (FDR < 0.05). Identification of motifs associated with snatched (B) and unsnatched (C) sequences.
273 Violin plots show the maximum activation distributions for snatched (S) and unsnatched (U) sequence categories in
274 arbitrary units. The four-nucleotide long motifs associated with each category are visualised as position weight
275 matrices. The positional enrichment of the four-nucleotide motifs across the 10mer sequences is shown. The number
276 of sequences is given as n above each bar chart.

277
278 [T/C][A/T][T/G/A]A motif was preferentially avoided by cap snatching if it occurred at any position
279 within the 10mer. To our knowledge this is the first evidence for the avoidance of particular
280 sequences as priming leaders by the IAV polymerase.

281 **Host genomic origin of over- and under-represented sequences**

282 Of 29,195 10mers, we assigned transcript identity to 12,992 (44.5%)(Methods) and of the named
283 10mers, 6,353 mapped to more than one transcript; for these, a single transcript was chosen at
284 random from the list of possible sites. 8,895 10mers had annotated host promoter/gene names
285 and did not contain IAV promoter-like sequences (Methods). The remainder are a mixture of
286 alternative host promoters, lncRNAs, eRNAs and other RNA species (Andersson *et al.*, 2014). This
287 approach costs statistical power, but is necessary to avoid any bias that might be introduced into
288 the identification based on a quantitative measure, such as abundance. We repeated the Fisher's
289 Exact analysis for all 10mers assigned to a gene name to provide summary data for that gene. The
290 1,000 most significantly enriched named genes in the snatched and not snatched sets are
291 reported in Table S 6.

292 A cap-snatching event can occur at any point after infection and before and RNA extraction from
293 the cells, therefore a more relevant background pool of host RNAs from which a given leader
294 could have been obtained may be the host RNA content at the preceding time point. Our dataset
295 allowed us to systematically compare every 10mer in infected cells against the background RNA in
296 the cell from the same time point, and also against the background RNA at a previous time point.

297 Genes that met this stringent threshold, for at least two donors at all time points, are reported

298 with a description of their function in Table S 6.


299 **Host transcriptional machinery is potentially targeted by the cap-snatching mechanism**

300 Key spliceosome snRNAs (*RNU1*, *RNU11*, *RNU12*, *RNU4ATAC*, *RNU5A*, *RNU5E*, *RNU5F*, *RNU5D*,
301 *RNU7*) and their variants/pseudogenes were high among the most significantly enriched named
302 genes. This is consistent with previous observations that snRNAs are snatched frequently and
303 shows that this may represent a true preference for these RNAs. In view of the preferential
304 snatching of multiple snRNAs, we considered whether specific classes of capped host RNAs might
305 be targeted. Of the RNA types we considered, only snRNAs were strongly preferentially snatched
306 (Figure S 5 A, B).

307 This sequencing method also allows the observation of histone mRNA which enabled us to
308 observe that 10mers corresponding to histone mRNAs were also significantly over-represented. In
309 addition, we observed that many host mRNAs encoding spliceosome- and transcription-
310 associated proteins (*SRSF3*, *SRSF6*, *PRPF18*, *SNRNP25*, *SNRNP70*, *MAGOH*) were preferentially
311 snatched. The 10mer corresponding to the transcript encoding the largest subunit of RNA
312 polymerase II (POLR2A), was 5.83-fold over-represented in snatched sequences (OR = 5.83; FDR
313 <0.05). *PABPN1*, which encodes poly(A) binding protein, was also preferentially snatched (OR =
314 2.28; FDR <0.05). These comprise key elements of both transcription and polyadenylation of host
315 mRNAs. Taken together these observations imply that cap-snatching may interfere with regulation
316 of transcription and splicing in the infected cell. However, POLR2B, another subunit of RNA
317 polymerase II, was 7.77-fold under-represented (OR = 0.13; FDR < 0.05) making it difficult to draw
318 simple conclusions. To rectify this, we performed gene set enrichment analysis to statistically
319 determine over- and under-represented pathways affected by the cap-snatching mechanism.

320 **Pathway enrichment analysis indicates that specific ribosome-associated transcripts are avoided** 321 **by the cap-snatching mechanism**

322 Identified transcripts from all time points and donors were collated and gene set enrichment
 323 analysis performed by querying various pathway/gene ontology datasets (listed in Table S 7).
 324 Querying Reactome gave a single over-represented pathway: RNA Polymerase II transcribes



325
 326 **Figure 3: Pathways that were enriched in snatched and unsnatched sequences.**
 327 (A) The 10 most under-represented pathways (negative enrichment score, blue) and single significantly over-
 328 represented pathway (positive enrichment score, orange) in the Reactome 2016 database are shown. N represents
 329 the number of genes associated with that pathway detectable in the dataset. p-values shown are Benjamini-
 330 Hochberg FDR-adjusted p-values. (B) Volcano plot showing the significance as $-\log_{10}(\text{FDR})$ and odds ratio of snatched
 331 versus unsnatched 10mers with members of the Reactome pathway 'RNA Polymerase transcribes snRNA genes'
 332 highlighted (snRNA, green diamonds, mRNA orange circles). (C) The same volcano plot as in (B) with members of the
 333 Reactome pathway 'Viral mRNA Translation' highlighted (blue circles).

334
 335

336 snRNA genes (Figure 3 A). A volcano plot highlighting the distribution of pathway members shows
337 that many mRNA pathway members were under-represented and the members of this pathway
338 that drive its enrichment as an over-represented pathway were predominantly snRNA transcripts
339 (Figure 3 B), particularly snRNA members of the minor spliceosome. This is consistent with the
340 observed preferential snatching of snRNAs. These transcripts were upregulated in IAV treated
341 MDMs compared to LPS treated MDMs (Figure S 5 C).

342 Pathway enrichment also allowed us to look for pathways that were avoided by the cap-snatching
343 mechanism. We identified pathways associated with translation and ribosome formation as
344 significantly under-represented in the cap-snatched pool (Figure 3 C). Although multiple pathways
345 were identified, these were not independent: these associations were largely driven by presence
346 of a group of transcripts encoding the same set of ribosomal proteins (Table S 7). These data
347 show that IAV avoids snatching caps from ribosomal mRNA transcripts. Interestingly, not all
348 mRNAs encoding ribosomal subunits were avoided. We compared our results to a recent study
349 reporting the effect of targeted knockdown of specific ribosomal subunit mRNAs in the context of
350 IAV infection (Wei *et al.*, 2019), but saw no clear relationship between cap-snatching preference
351 and viral protein production, host protein production, or antigen presentation.

352 The 10mers associated with the ribosomal protein transcripts in question, and their pseudogenes,
353 which are generally indistinguishable at the 10mer level, were extracted and aligned using Meme
354 (Bailey and Elkan, 1994). Amongst the analysed 10mers the most commonly observed motif was
355 CTCTT[T/C]C[T/C] ($p < 0.05$) (Figure S 5 D) originating at the first position. This is broadly in
356 agreement with our observation above that CTAG occurring at various positions within the 10mer
357 is unlikely to be snatched by IAV, regardless of abundance.

358 Discussion

359 This comprehensive analysis of host and viral transcripts reveals key features of host-pathogen
360 interaction at a molecular level. We demonstrate that IAV cap-snatching has a strong preference
361 for host transcripts associated with splicing and transcription, and avoids host ribosomal subunit
362 transcripts. By comparing against a canonical innate immune stimulus, LPS, we systematically
363 characterise the host response of human macrophages to IAV exposure.

364 **Characteristics of MDM response to IAV**

365 MDMs can be infected with IAV and produce both viral protein (NP) and infectious virus.
366 This initial permissiveness may be related to the fact that *IFITM3*, the protein product of which
367 restricts viral infection and is associated with IAV susceptibility (Everitt *et al.*, 2012), was almost
368 completely down-regulated in MDM compared to the high level of expression in blood monocytes
369 (can be observed at <http://fantom.gsc.riken.jp/zenbu/>).

370 Wang *et al.* (Wang *et al.*, 2012) discussed the possible cellular pattern receptors required for
371 recognition and response to IAV infection in MDMs. Of those candidates, mRNAs encoding RIG-I
372 (DDX58), MDA-5 (IFIH1) and TLR3 were expressed at very low levels in MDMs. In contrast, TLR7
373 was expressed at similar levels in MDM to the level in plasmacytoid dendritic cells
374 (<http://fantom.gsc.riken.jp/zenbu/>) and thus appears the most likely initial intracellular receptor
375 that initiates the response to viral nucleic acid.

376 Examination of co-expression clusters suggests that in MDMs IAV does not cause a selective or
377 global loss of transcription of host-related genes. The GO enrichment for the largest cluster
378 observed, Cluster 1 (Table S 2), included the ubiquitin-proteasome complex, oxidative
379 phosphorylation, cell cycle and transcriptional regulation including mRNA splicing and binding.
380 Together with the consistent similarity in global gene expression between uninfected and early
381 post-infection time point, this suggests that most basic cellular processes are maintained during
382 infection. In A549 cells, IAV infection causes cell cycle arrest (He *et al.*, 2010), and down-
383 regulation of cell-cycle associated genes. Since MDM are not actively proliferative, the apparent

384 induction by IAV infection of many cell cycle-related genes, including the cyclin genes *CCNA1*,
385 *CCNB1*, *CCND1*, *CCNE1*, *CCNE2* and *CCNG2* and 19 genes encoding multiple cyclin-dependent
386 kinases (CDK) is unlikely to be associated with cellular proliferation.

387 The gene set induced by IAV infection likely includes many additional anti-viral effectors. For
388 example, the gene encoding BST2-tetherin, which inhibits the release of enveloped virus particles,
389 possibly including some strains of IAV (Gnirß *et al.*, 2015) was induced by both LPS and IAV. A
390 neighbouring gene, *MBV12A*, shares a bidirectional promoter with *BST2*, a subunit of the ESCRT
391 complex, over-expression of which interferes with viral assembly in HIV-1 infected cells (Morita *et*
392 *al.*, 2007). *MBV12A* was much more strongly induced by IAV than *BST2* in MDM, and was only
393 marginally induced by LPS in the same cells. Similarly, expression of the antiviral effector *RSAD2*
394 (viperin) (Wang, Hinson and Cresswell, 2007; Gizzi *et al.*, 2018) was induced at 2 and 7 hours.

395 Many other inducible genes in Cluster 1, including multiple members of the *FOX*, *TRIM*, *CDK*,
396 *USP* and *MED* families have been shown to be phosphorylated during the MDM in response to IAV
397 (Söderholm *et al.*, 2016) and are implicated as antiviral effectors (Nyman *et al.*, 2000; Ohman *et*
398 *al.*, 2009).

399 A feature of Cluster 2 that is not evident from GO annotation, is the ablation within 7 hours of
400 transcripts encoding many cell surface receptors and signalling molecules with roles in innate
401 immunity, including *CSF1R*, *C3AR1*, *C5AR1*, *CD4*, *CD14*, *MYD88*, *CD180*, *CD44*, *CD163*, *FCGR2A*,
402 *IL10RB*, *ITGAM*, *ITGAX*, *TLR1*, *TLR4*, *TLR8*, *TNFRSF1A*, and *TGFBR1*.

403 **Variation in host transcript expression between donors**

404 Substantial variation amongst MDMs from different individuals was evident in most IFN-inducible
405 genes. Fairfax *et al.* (Fairfax *et al.*, 2014) reported that up to 80% of inducible genes in human
406 monocytes responding inflammatory stimuli show evidence of heritable variation in their level of
407 expression. Since genetic variation between hosts alters risk of death from influenza (Horby *et al.*,
408 2012), and variants underlying inter-individual variation in IAV-induced gene expression are

409 associated with human disease phenotypes (Lee *et al.*, 2014), we quantified variation in inducible
410 expression among the four donors in this study. The coefficient of variation for named genes at
411 each time point is provided in Table S 8. The antiviral *IFITM3* and the neighbouring *IFITM1* were
412 selectively inducible in Donor 3, albeit to low levels (Figure S 6 A, B). Fairfax *et al.* also found
413 trans-acting expression variants, likely involving autocrine *IFNB1* signalling upstream of separate
414 regulons targeted by the transcription factors *IRF7* and *IRF9* (Hume and Freeman, 2014). One of
415 the four donors in our study, Donor 1 showed a more rapid induction of *IFNB1* in response to IAV,
416 which preceded high *IRF7* and *IRF9* induction (Figure S 6 C, D). Conversely, cells from Donor 4 had
417 a relatively low *IFNB1*, *IFNA1* and *IRF9* induction in response to IAV, whereas *IRF3* was relatively
418 stable throughout infection in all four donors (Figure S 6 E-G).

419 **The comparison between the host response in IAV and LPS treated MDMs**

420 Like LPS, IAV strongly induced *TNF α* , *IL1B*, multiple chemokine genes (e.g. *CCL2*, *CCL3*, *CXCL1*,
421 *CXCL2*, *CCL20*) and many genes for immediate early transcription factors (e.g. *EGR* family, *FOS*
422 family, *JUN* family, *NR4A1*, *ATF3* etc.). However, the global gene-based analysis of the response of
423 MDM to IAV reveals a clear contrast to the LPS response in MDMs. In LPS-treated human MDMs
424 mRNA levels of proinflammatory genes are subject to control by a complex network of rapidly-
425 inducible feedback regulators including *DUSP1*, *TNFAIP3*, *NFKBIA*, *ZC3H12C*, *PTGS2* and the
426 microRNA *mIR-155* (Baillie *et al.*, 2017). The sustained induction of proinflammatory transcripts in
427 response to IAV contrasts with this transient induction in response to LPS. Each of these feedback
428 regulators was induced to a lesser extent and/or much later in the response, by IAV compared to
429 LPS.

430 Unlike Hoeve *et al.*, (Hoeve *et al.*, 2012) we did not detect expression of transcripts encoding either
431 of the subunits of *IL12* (*IL12A*, *IL12B*), prior to the 24 hour sample, in MDM in response to IAV.
432 Following LPS treatment, MDM have low expression of *IL12A* (p35) (Figure S 2 B), instead inducing
433 *IL23A* and *IL12B* mRNA, which together encode the heterodimeric proinflammatory cytokine *IL23*.

434 These were not detected in IAV-infected cells. Similarly, there was no detectable induction of the
435 anti-inflammatory cytokine *IL10* mRNA by IAV, in contrast to the massive and sustained induction
436 by LPS.
437 The type III interferons were highly specific to IAV-treated MDMs. These were recently shown to
438 mediate a key mechanism preventing viral spread to the lower respiratory tract in mice
439 (Klinkhammer *et al.*, 2018), which is believed to cause life-threatening disease in humans (Van Riel
440 *et al.*, 2007). The sustained induction of IFN responsive genes (Cluster 1, see above) shows that
441 induction of IFN and IFN signalling is clearly not successfully prevented by the primary IAV
442 interferon antagonist NS1 in MDM, by contrast to the pattern observed in other cell types (Haye
443 *et al.*, 2009; Jia *et al.*, 2010; Thakar *et al.*, 2013; Perez-Cidoncha *et al.*, 2014). The observed
444 constraint on production of new virus may be attributed to the massive interferon response
445 (Cluster 1, see above), and down-regulation of synthesis of secreted proteins (Cluster 2, see
446 above). This profound difference in induction of IFN-responsive genes between LPS and IAV
447 stimulation is reflected in blood transcriptome profiles of patients with severe IAV compared to
448 those with bacterial sepsis (Ramilo *et al.*, 2018).

449 **Elimination of bias for accurate quantification of leader sequences and 5' RNA ends**

450 Our choice of sequencing methodology and analytical approach eliminated numerous sources of
451 bias that have limited the interpretation of previous studies of cap-snatching preference. A key
452 difference from previous work is the accurate quantification of background transcription, which
453 enables the first accurate quantification of the transcripts *not* snatched by IAV.
454 The HeliScope single molecule CAGE sequencing methodology has several key advantages. This
455 method sequences transcripts from the 5' end without internal segment-specific primers, and
456 without PCR amplification (Kanamori-Katayama *et al.*, 2011). In contrast, previous studies of IAV
457 virus transcripts used internal primers for the viral segments (Koppstein *et al.*, 2015; Sikora *et al.*,
458 2017) or performed library amplification on cDNA derived from capped RNA (Gu *et al.*, 2015).

459 In addition, our use of terminal-depth sequencing limits noise and sampling error, in both the
460 snatched sequences and the background distribution. Since CAGE reads sequences directly from
461 the 5' end, we can be confident that we have quantified the background pool of potential leader
462 sequences that were available to be snatched. By limiting our analysis to sequences of a specific
463 length (10mers), we eliminate bias that may occur due to differential mapping or identification of
464 sequences of different lengths.
465 Our timecourse design allows us to mitigate another potential source of bias. An unknown period
466 of time has passed between a cap-snatching event and RNA extraction from the cells. Therefore,
467 the relevant background pool of host RNAs from which a given leader could have been obtained is
468 the host RNA content at a previous time. We systematically compared every enriched sequence in
469 infected cells against the background RNA in the cell from the same time point, and against the
470 background RNA at a previous time point (Table S 6).

471 **Host mRNA processing machinery is preferentially targeted by IAV cap-snatching**

472 Non-coding RNAs, particularly snRNAs, have been identified as the source of the most frequently
473 snatched leader sequences (Gu *et al.*, 2015; Koppstein *et al.*, 2015). However, it was unclear
474 whether this frequency reflected their relatively high abundance or true over-representation of
475 this RNA type among leaders. Our use of terminal-depth sequencing of complete 5' sequences,
476 combined with our focused analysis on 10mers, enables an unbiased, accurate quantification of
477 the abundance of each sequence in both the snatched, and unsnatched, sequence sets.

478 Differential expression analysis revealed that all snRNAs, apart from RNU1, were upregulated in
479 IAV treated MDMs compared to LPS (Figure S 5 C). Notably, snRNA components of the minor
480 spliceosome (*RNU11*, *RNU12*, *RNU4ATAC*, *RNU5A* and *RNU5E*) were highly preferentially snatched,
481 particularly at 2 and 7 hours. In the FANTOM5 dataset, the components of the minor spliceosome
482 were most expressed in the later time points of MDM infection with IAV (can be viewed in Zenbu
483 Browser). *RNU6ATAC* is the only snRNA component of the minor spliceosome we did not observe

484 to be snatched, despite upregulation during IAV infection. This mRNA is transcribed by RNA
485 polymerase III (Singh and Reddy, 2006; Canella *et al.*, 2010) leading to a different cap structure
486 which may not be recognised by the IAV polymerase (Koppstein *et al.*, 2015). The minor
487 spliceosome splices <1% of introns in the human genome and its activity – and hence functional
488 expression of these splice variants – is regulated by *RNU6ATAC* and increased by signalling
489 through the p38MAP kinase pathway (Younis *et al.*, 2013). The viral NS1 protein is known to
490 inhibit the formation of *RNU12/RNU6ATAC* complexes (Wang and Krug, 1998). Our results
491 suggest that IAV may have evolved more than one mechanism to suppress gene expression
492 through the minor spliceosome pathway.

493 **RNA that codes for ribosomal subunits is avoided by IAV cap-snatching**

494 Our comparison of LPS and IAV-treated cells shows that genes encoding ribosomal subunits are
495 highly differentially transcribed in IAV-treated cells. Therefore, if cap-snatching were primarily
496 determined by abundance, as previously thought (Sikora *et al.*, 2017; De Vlugt, Sikora and Pelchat,
497 2018), we would expect to see leader sequences derived from ribosomal genes prominently
498 among the snatched sequences. Explorations of leader sequence analysis have focused on the
499 snatched population of sequences out of necessity. Our analysis allowed us to determine those
500 sequences that remained unsnatched in the host cell. Although we do see a minority of ribosomal
501 protein mRNA snatched, IAV cap-snatching exhibited a surprisingly strong avoidance of mRNAs
502 encoding ribosomal proteins, which is particularly evident in our pathway enrichment analysis.
503 Recent evidence shows that altering the relative abundance of particular protein subunits of the
504 ribosome can specifically affect the presentation of IAV encoded proteins by MHC-I (Wei *et al.*,
505 2019). This suggests the hypothesis that the virus has evolved to avoid inadvertently altering
506 ribosome abundance and/or composition in a manner would be deleterious to its own replication.

507 **Limitations of this study**

508 Our study was limited to one cell type and one strain of IAV. It is to our knowledge the most
509 comprehensive systems-level evaluation of both host and viral transcriptional activity for IAV
510 replication, and the first study to perform an unbiased quantification of cap-snatching preference
511 compared with accurate measurement of background transcription. It is possible that the
512 observed enrichment of capped snRNA may be specific to MDMs. Given the high prevalence of
513 snRNA in the IAV leader sequence population of H1N1 infected A549 cells in other studies (David
514 Koppstein, Ashour and Bartel, 2015; Gu, Glen R. Gallagher, *et al.*, 2015), it is reasonable to
515 speculate that this mechanism is generalizable across IAV- infected cell types. Future work is
516 needed to explore the mechanisms underlying the preference and avoidance of specific mRNAs,
517 and to determine cap-snatching preferences of other IAV strains and in other cell types.

518 **Conclusions**

519 Our combined analysis of host and viral transcriptomes of IAV-infected human MDMs and
520 comparison with the response to LPS reveals IAV-specific features of the host response. In
521 overview, we suggest that MDMs contribute to host defence against IAV in multiple ways. Firstly,
522 MDMs internalise virus and produce viral proteins, but they undergo cell death without
523 generating large numbers of progeny virus. These activities lead directly to viral clearance and
524 since MDMs are professional antigen-presenting cells, also promote presentation of viral antigens
525 to T cells. Secondly, in response to IAV, MDMs generate sustained high levels of multiple
526 interferons providing protection against infection of neighbouring cells, including incoming
527 inflammatory cells. On the other hand, the inability of IAV to induce feedback regulators such as
528 IL10 was associated with induction of proinflammatory cytokines that was transient in LPS-
529 stimulated cells but sustained in IAV-infected cells. This failure of feedback regulation may
530 contribute to pulmonary inflammation that is a feature of severe IAV pathology in a clinical setting
531 (Teijaro, 2014). Finally, many genes encoding surface receptors and signalling molecules required
532 for recognition and response to bacteria such as *CD14* and *TLR4* were down-regulated during IAV

533 infection, which may increase susceptibility to secondary bacterial infections that produce
534 morbidity and mortality in IAV infected patients (Morris, Cleary and Clarke, 2017).
535 HeliScope CAGE at terminal depth allows for an unbiased observation of both IAV segment mRNA
536 and host-derived leader sequences in cap-snatching. Our comprehensive analysis of leader
537 sequences identified motifs that the IAV polymerase may favour and two others that it apparently
538 avoids during the snatching process. We discovered strongly preferential cap-snatching of host
539 sequences associated with splicing, with evidence of the avoidance of key cellular components
540 required for viral replication. These results hint at a mechanism of host evasion through which IAV
541 may downregulate RNA processing machinery through cap-snatching while specifically evading
542 altering translational machinery specifically required for the replication of the virus.

543 **Materials and Methods**

544 **Ethics, cell culture, virus propagation and infections**

545 Cells were isolated from fresh blood of volunteer donors under ethical approval from Lothian
546 Research Ethics Committee (11/AL/0168). Primary CD14⁺ human monocytes were isolated from
547 whole blood as described previously (Irvine *et al.*, 2009) from 4 human donors. Monocytes were
548 plated for 7 days in RPMI-1640 supplemented with 10% (vol/vol) FBS, 2 mM glutamine, 100 U/ml
549 penicillin, 100 µg/ml streptomycin (Sigma Co.), and 10⁴ U/ml (100 ng/ml) recombinant human
550 colony-stimulating factor 1 (rhCSF1; a gift from Chiron, Emeryville, CA, USA) for differentiation into
551 macrophages. Cells were maintained at 37°C with 5% CO₂. A/Udorn/72 (H3N2) was generated as
552 described previously (Hoeve *et al.*, 2012). Differentiated macrophages were infected on day 8.
553 Cells were washed in serum free media after which they were infected at MOI 5 in a volume of
554 200µl infection media. Cells were incubated for 1 hour at 37°C then washed three times with
555 serum-free media and incubated in RPMI-1640 supplemented with 1µg/ml TPCK-trypsin, 0.7%
556 BSA, 2mM glutamine, 100 U/ml penicillin, 100 µg/ml streptomycin (Sigma Co.), and 10⁴ U/ml (100

557 ng/ml) rhCSF1. Samples were collected at 4 time points post infection/media change: 0 hour (1
558 hour after addition of the virus), 2 hours, 7 hours and 24 hours. Uninfected samples were also
559 collected at 0 and 24 hours. LPS treatments were carried out as described previously (Baillie *et al.*,
560 2017). Briefly, cells were treated with 10ng/ml bacterial lipopolysaccharide (LPS) from salmonella
561 Minnesota R595 and harvested at time points from 15 minutes to 48 hours after treatment. Only
562 time points with corresponding IAV treated time points were used in this analysis.

563 **CAGE**

564 RNA was extracted using the Qiagen miRNeasy mini kit (217004). RNA quality was assessed and
565 CAGE was performed as described previously (Takahashi *et al.*, 2012) as part of the FANTOM5
566 project. Virus genome information is available in Table S 9.

567 **Data Analysis**

568 Computational analysis was performed using custom Python scripts and as described previously
569 (Forrest *et al.*, 2014). Custom Python scripts are available at:
570 https://github.com/baillielab/influenza_cage.

571 **Network Analysis of the MDM transcriptome during infection.**

572 Network analysis of the MDM transcriptome during infection was carried out using Graphia
573 Professional (Kajeka Ltd., United Kingdom; <http://www.kajeka.com>) -formerly Biolayout *Express*^{3D}.
574 Results were filtered to exclude any transcript where the maximum value across all samples did
575 not reach 10 tags per million (TPM). The sample-to-sample analysis was performed at a Pearson
576 correlation coefficient of ≥ 0.70 . The gene-to-gene analysis was performed at a Pearson
577 correlation coefficient of ≥ 0.94 and used a relatively coarse Markov cluster algorithm inflation
578 value of 1.7 to avoid excessive cluster fragmentation. We restricted the analysis to the dominant
579 promoters (p1) and used averaged data from the 4 donors.

580 **EdgeR analysis of LPS treated versus IAV treated samples.**

581 Differential expression between groups of genes was analysed using the EdgeR package
582 (Robinson, McCarthy and Smyth, 2009) in R version 3.5.1. CAGE data for LPS and IAV datasets
583 were processed as described previously (Baillie *et al.*, 2017). Briefly, for each treatment, the
584 expression value for each clustered transcription start site (CTSS) was compared to the expression
585 values of the corresponding time points from all other donors. Values deviating >3SD from the
586 mean of this pool were replaced with the average of the pool. An average expression value for
587 each CTSS from all donors was then calculated. CTSS with a minimum expression level of 10 tags
588 per million in at least one comparable time point, and with a coefficient of variation > 0.5, were
589 included in expression analysis. Samples corresponding to 7 hours post-treatments were carried
590 forward for analysis. We used the glmFit function to fit the models and glmLRT to perform testing
591 between the LPS and IAV treated samples. Benjamini-Hochberg correction was applied to p-
592 values. A significance threshold of FDR < 0.05 was used.

593 **Identification and analysis of IAV mRNA**

594 Capped IAV RNAs were identified by the conserved 11 base promoter sequence expected to be in
595 all viral mRNA ('GCAAAGCAGG'), as described in the text. Sequences that contained the
596 promoter were classified as capped viral mRNA and aligned to the Udorn genome (Table S 9) using
597 custom Python scripts.

598 **Unbiased analysis of leader sequence preference**

599 The first ten nucleotides of each CAGE tag (10mers) that reached the abundance threshold in our
600 dataset were extracted and this set of unique 10mers were used in subsequent analysis. The
601 abundance threshold was set to 1,000 occurrences across all samples. To determine the 10mer
602 sequences that were over- and under-represented in the snatched population based on
603 background abundance, the number of times a 10mer was associated with the IAV promoter was
604 counted ("snatched") along with the number of times the 10mer occurred without the promoter
605 ("unsnatched"). These were analysed using Fisher's Exact test. Benjamini-Hochberg correction

606 was applied to p-values. Significance was determined by an FDR < 0.05. The number of times a
607 10mer was snatched was compared to the number of times it occurred unsnatched at the
608 previous time point by Fisher's Exact test.

609 **Analysis of leader motifs using convolutional neural networks**

610 A sub-set of 10mers that reached the following threshold: $0.3 < (OR) > 3$, $-\log(\text{FDR} < 10)$ were
611 brought forward for analysis of motif preference using convolutional neural networks. We
612 optimised an existing network (Budach and Marsico, 2018) for our use by using altering the
613 parameters to find suitable setting by using the grid search to explore various kernel lengths (2, 3,
614 4, and 5) and drop rate (0, 0.1, and 0.5); for other parameters, we used the default settings of
615 Pysster (kernel number: 20, convolutional layer number: 2) apart from learning rate at 0.0001 and
616 patience, stopping at 100. Since our analysis was restricted to 10mers, we did not use the pooling
617 method. We randomly selected the training set and validation set in the proportion of 60% and
618 30% independently. The purpose of this experiment was to explore the existing data, not to make
619 predictions, so we reused the training data to explore the result. Optimisation experiments
620 demonstrated that a kernel length of 4 gave us relatively high, and relatively consistent, precision
621 and recall. We maximised the area under the receiver operator characteristic (ROC) and the area
622 under the precision recall curve. Motifs were considered if they reached a score of at least 50%
623 the maximum score for that time point.

624 **Assignment of transcript identity to 10mer sequences**

625 CAGE tags were mapped to the human reference genome (hg19) as described (Forrest *et al.*,
626 2014). To identify the possible transcription start site from which a 10mer arose, we extracted
627 every possible chromosomal location for a 10mer that met the abundance threshold of 1000
628 across all samples from the original alignment BAMfiles created as part of the Fantom5 project.
629 10mers containing a 6mer from within the IAV promoter ('GCAAAA', 'CAAAAG', 'AAAAGC',
630 'AAAGCA', 'AAGCAG', 'AGCAGG') were removed. Reference transcription start sites were

631 downloaded from Fantom5. Promoter identity was assigned first using BEDtools 2.25.0 with a
632 window of +/- 5 bases and exact strand match only. For each possible promoter identity the
633 10mer was mapped to the genomic sequence with a window of +/- 5 bases directly surrounding
634 the coordinates of the assigned transcription start site and exact matches only were used to assign
635 promoter identity.

636 In order to avoid any effect of abundance that may bias transcript identification, for 10mers with
637 more than one possible promoter identity, a site was chosen at random from the list of possible
638 sites. Promoter names were converted to HGNC format. To determine over- and under-
639 representation of promoters and genes, all 10mers that were assigned to that promoter or gene
640 name were counted and the Fisher's Exact test was performed. Benjamini-Hochberg FDRs were
641 calculated using the `scipy.stats v 0.18.1 statsmodels.stats.multitest.multipletests` function with
642 method = 'fdr_bh'. Significance was determined by an FDR < 0.05. RNA type was assigned to gene
643 names using reference data downloaded from Biomart (<http://www.ensembl.org>). Only named
644 transcripts were assigned an RNA type.

645 In order to determine if a gene was significantly snatched compared to its abundance at the
646 previous time point, we compared snatched at t to unsnatched at t-1 for the collated values of all
647 10mers that were assigned that gene name in each sample separately. This was performed for
648 2hrs versus 0hrs, 7hrs versus 2hrs, and 24hrs versus 7hrs. A gene was declared 'True' if the
649 combined p-value for that gene was significant in 2 out of 4 donors at that time point.

650 **Pathway and Gene Set Enrichment Analysis**

651 All named genes that appeared significant were included in this analysis. Gene names were
652 converted to HGNC format for consistency with gene set libraries, excluding unannotated peaks
653 and names with no HGNC equivalent. GO term assignment and pathway analysis for coexpression
654 clusters were performed using Enrichr (mp.pharm.mssm.edu/Enrichr) (Chen *et al.*, 2013; Kuleshov
655 *et al.*, 2016) and GATHER (Chang and Nevins, 2006). Pathway databases queried were: Reactome

656 2016, KEGG 2016, WikiPathways 2016 and GO Molecular Function 2015, GO Cellular Component
657 2015 and GO Biological Process 2015. Gene Set Enrichment analysis on ranked cap-snatching
658 preference data was performed using R package FGSEA (Sergushichev, 2016), in R version 3.5.1,
659 with the following parameters: set.seed = 42, min set size = 5, max size = 5000, nproc = 1, nperm =
660 1000000. Gene set libraries KEGG 2016, BioCarta 2016, Reactome 2016, WikiPathways 2016, NCI
661 Nature 2016, GO Biological Process 2018, GO Molecular Function 2018, and GO Cellular
662 Component 2018 were used. Genes were ranked by $-\log_{10}(\text{p-value})$, and $\log_{10}(\text{OR})$. Benjamini-
663 Hochberg correction was applied to p-values.

664 **Supplementary methods**

665 **Immunofluorescence**

666 Primary human monocyte derived macrophages were differentiated, as described above, on glass
667 coverslips. Cells were infected as described. At 0, 2, 7, and 24 hours post infection cells were fixed
668 for 20 min in 4% formaldehyde in PBS. After permeabilization with 0.2% Triton X-100 in PBS for 5
669 min at room temperature, cells were incubated with mouse monoclonal influenza A NP AA5H
670 (BioRad) at 1:500. After 1 hour cells were washed three times with PBS and incubated with goat
671 anti-mouse Alexa Fluor 488 at 1:1000 (ThermoFisher). After 1 hour cells were washed three times
672 with PBS and incubated in DAPI (ThermoFisher) for ten minutes after which they were washed
673 three times with PBS and mounted on slides using VECTASHIELD® Antifade Mounting Medium.
674 Cells were viewed on a Leica fluorescence upright microscope and imaged using a Hamamatsu
675 Orca-ER low light mono camera. Scale bars were added using ImageJ.

676 **Cell viability and Virus Titration**

677 Cell viability was measured using Cell Titre Glo® at 0, 2, 7, and 24 hours post infection. Virus
678 produced was titrated by plaque assay on MDCK cells. Virus titres in cell supernatants were
679 determined by plaque titration using ten-fold serial dilutions of virus stocks. Confluent MDCK cells
680 in 6 well plates were inoculated with cell supernatant for 1 hour in serum-free medium. An
681 overlay (mixture of equal volume of DMEM and 2.4% Avicel (Sigma-Aldrich, UK) supplemented
682 with 1 µg/ml TPCK-treated trypsin and 0.14% BSA fraction V) was then put onto the wells. After
683 48 hours, cells were fixed using 3.5% formaldehyde and stained with 0.1% crystal violet. Virus
684 titres were calculated by plaque count*dilution factor/(volume of inoculum) and expressed as
685 plaque forming units per millilitre of supernatant (pfu/ml).

686 **Identification of potential alternative splice variants**

687 CAGE tags containing a leader sequence and an IAV promoter sequence followed by a sequence
688 that did not align proximal to the IAV promoter sequence in the Udorn genome were extracted.
689 These novel 'promoter proximal' sequences were hypothesised to be derived from putative 5'UTR
690 sequences internal to a segment arising from mRNA from splice variants. These sequences were
691 aligned throughout the Udorn genome using custom Python scripts. The abundance of each
692 sequence was divided by the number of locations in the Udorn genome it could map to. The
693 weighted abundances at each position were then summed and graphed. Segment 7 mRNA3 was
694 used as a proof of principle.

695 **Determination of Coefficient of Variation Across 4 Donors**

696 The expression profile of CTSS across all samples was extracted from the Fantom5 data in TPM
697 (tags per million). The coefficient of variation for each gene was calculated for each of the 6
698 treatments across the 4 donors ($SD:Mean * 100$). Gene names were assigned to CTSS by Bedtools
699 overlap with a window of +/- 5 bases using the hg19 annotation from Fantom5. Unnamed genes
700 were removed from the final list. Results were separated by treatment.

701

702 **Supplementary Results**


703 **Potential alternative splice variants**

704 Splicing has been observed in segments 7 and 8 of IAV. In particular, in segment 7 the splice donor
705 site for the mRNA3/M3 transcript is found at the end of the promoter sequence (Lamb, Lai and
706 Choppin, 1981) . Over 400,000 reads contained the IAV promoter sequence and a leader
707 sequence, but did not originate from the genome sequence proximal to the promoter in any of
708 the 8 segments. The leader and promoter sequences were removed and the sequences aligned
709 throughout the Udorn genome. In order to quantify RNA expression at these loci, we summed the
710 weighted abundances of reads originating at the same position. This revealed 6,902 putative
711 capped IAV RNA sequences from the IAV genome, including the known splice variant of segment
712 7, the mRNA3 transcript (Figure S 3 D). The alignments observed (Table S 5) are likely to include
713 previously unidentified splice variants. However, in a systematic search, no putative IAV splice
714 variant RNA was preceded by a canonical major spliceosome acceptor site, apart from the mRNA3
715 transcript. It is possible these represent variants that are expressed in such low amounts they are
716 not detectable by other means, for example northern blot or radioactive primer extension. It is of
717 interest to determine if these putative mRNAs are true transcription products and if their
718 transcription and translation contributes to viral pathogenesis.

719

720

721 Supplementary Figures and Tables:



745 **Figure S 1: Characterisation of human monocyte derived macrophages productively infected with IAV.**

746 (A) Experimental outline. Blood was taken from 4 human donors, with appropriate ethical approval. CD14+

747 monocytes were extracted using magnetic beads and cultured in CSF1 for 8-10 days. MDMs were infected with

748 A/Udorn/72 (H3N2) at a multiplicity of infection of 5. At 4 time points (0, 2, 7, and 24 hours after medium change) the

749 cells were collected and RNA isolated. (B) Human MDMs were immunofluorescently stained for viral nucleoprotein to

750 confirm infection at 0, 2, 7, and 24 hours post infection. Scale bars 10 μ m. (C) Viral titre was measured by plaque


751 assay at 0, 2, 7, and 24 hours post infection (n = 3 independent experiments) and shown in pfu/ml supernatant. (D)

752 Cell viability was measured using Cell Titre Glo® at 0, 2, 7, and 24 hours post infection (n = 3 independent

753 experiments).

754

755



756 **Figure S 2: The transcriptional landscape between individual donors in response to IAV.**

757 (A-B) Comparison of the temporal response of transcripts between IAV- and LPS- treated MDMs. Relative expression
758 of selected genes in LPS- treated (red) and IAV- infected (blue) human MDMs at 0, 2, 7, and 24 hours post treatment is
759 shown in tags per million (TPM). Solid lines show the mean expression of all donors, filled-in area shows standard
760 deviation between donors. (n = 3 for LPS, n = 4 for IAV). Filled-in area shows standard deviation between donors.


761

762

763



764

765



B

Sample	Percentage of influenza Capped mRNA	Sample	Percentage of influenza Capped mRNA
MI_0h_donor1	0.00064731	Ud_2h_donor1	13.002863
MI_0h_donor2	0.00051712	Ud_2h_donor2	1.95856186
MI_0h_donor3	0.00039018	Ud_2h_donor3	0.37208457
MI_0h_donor4	0.00027346	Ud_2h_donor4	8.18392559
MI_24h_donor1	0.00066028	Ud_7h_donor1	7.07393336
MI_24h_donor2	0.00061248	Ud_7h_donor2	11.1807212
MI_24h_donor3	0.00038335	Ud_7h_donor3	8.1557241
MI_24h_donor4	0.00049407	Ud_7h_donor4	2.58876623
Ud_0h_donor1	0.14316053	Ud_24h_donor1	1.80209375
Ud_0h_donor2	0.1028579	Ud_24h_donor2	2.29903026
Ud_0h_donor3	0.02431418	Ud_24h_donor3	0.76502118
Ud_0h_donor4	0.01522597	Ud_24h_donor4	0.52302417



793

794

795


796

797 **Figure S 3: The amounts of IAV mRNA differed substantially between donors.**

798 (A) The raw number of IAV promoter-containing CAGE tags were counted, separated by segment sequence (see
799 legend and below), shown alongside to those in the same sample that did not contain the viral promoter sequence
800 (black). (B) Frequency, as percentage, of IAV promoter- containing CAGE tags in each sample. (C) The relative
801 amount, compared to the total amount of viral mRNA, of mRNA from each viral segment was calculated for individual
802 donors at each of the four timepoints. Height of the bar represents the mean frequency between donors. Error bars
803 show standard deviation. (D) The positions of potential splice variant sequences aligned to the Udorn genome are
804 shown as adjusted abundance. The known mRNA3 splice variant in segment 7 is shown (blue arrow). Time points and
805 donors have been collated to increase signal.

806


807
808
809
810
811
812
813
814
815
816
817
818
819
820
821
822
823
824
825
826
827
828
829
830



831 **Figure S 4: Precision Recall and Receiver Operator Curves for convolutional neural network analysis of 4**
832 **nucleotide length motifs in 10mer datasets.**

833 Models were trained and evaluated according to their receiver operating characteristic (ROC) area under the curve
834 and Precision Recall area under the curve. The values for total area under the curve (AUC) are given. Each of the four
835 time points was calculated independently.


836



837 **Figure S 5: The IAV polymerase does snatch based on RNA type**

838 (A, B) RNA type was assigned to 10mers based on transcript identity. Only 10mers with transcript identity were
 839 included. The significance of RNA type snatching was compared using ANOVA. RNA types were plotted against $-\log_{10}(\text{FDR})$ for 10mers of that type. The box denotes the interquartile range. The within the box represents the
 840 average and the whiskers represent standard deviation. The individual data-point for each 10mer is also plotted. The
 841 number of 10mers attributed to each RNA type is given as n above the box. (C) Differential gene expression analysis
 842 comparing expression of transcripts in LPS treated and IAV treated monocyte derived MDMs. Transcripts with a
 843 relative log fold change ($\log_2\text{FC}$) ≥ 3 and a $-\log_{10}(\text{FDR}) \geq 5$ are shown in red (higher in LPS treated) and blue (higher in
 844 IAV infection). Components of the minor spliceosome are shown in green, while components of the major
 845 spliceosome are shown in purple. (D) MEME analysis of 10mers taken from human gene sequences corresponding to
 846 the first ten nucleotides of ribosomal protein mRNAs.
 847

848



849

850 **Figure S 6: Variation in expression of interferon related genes between donors.**

851 Expression of the named genes at each of the four time points (0, 2, 7, and 24 hours post infection) was compared
852 between donors (n=4). Expression is given in arbitrary units (A.U). Lines represent individual donors, as shown in
853 legend.

854

855

856

857 **Supplementary Table Legends**

858 **Table S 1: Clustering of transcripts expressed in IAV- infected MDMs.**

859 Analysis was restricted to the dominant promoters (p1) and used averaged data from the 4
860 donors. A Pearson correlation coefficient threshold of 0.94 and an MCL of 1.7 was used.

861 **Table S 2: GO term enrichment of the top 10 clusters.**

862 Analysis was performed using GATHER (Chang and Nevins, 2006).

863 **Table S 3: Enrichr analysis of the top 10 clusters.**

864 All results shown reach the threshold FDR < 0.5. Databases queried were Reactome 2016, KEGG
865 2016, and Wikipathways2016 (Kuleshov *et al.*, 2016) .

866 **Table S 4: Differential expression analysis of LPS- and IAV- treated MDMs.**

867 Analysis was performed using edgeR. All transcripts with a $-\log_2(\text{Fold Difference}) \geq 1$ are shown.

868 **Table S 5: mRNA sequences for putative splice variants.**

869 **Table S 6: The most significantly and consistently snatched and unsnatched genes.**

870 All results shown reach the threshold FDR < 0.5.

871 **Table S 7: Fast preranked gene set enrichment analysis (FGSEA) of under- and over- represented 872 10mers.**

873 **Table S 8: Coefficient of variation for named genes at each time point.**

874 The coefficient of variation for named genes. Expression at CTSS were compared across donors
875 (n=4) and annotated using publicly available Fantom5 annotation.

876 **Table S 9: Details of Udorn sequences used to assign identity to segments.**

877 Provided in Fasta format.

878

879 **Acknowledgements**

880 The authors would like to thank Ross Hendry for advice on python code.

881 JKB gratefully acknowledges funding support from a Wellcome Trust Intermediate Clinical

882 Fellowship (103258/Z/13/Z), a Wellcome-Beit Prize (103258/Z/13/A) , and the UK Intensive Care

883 Society. DAH, PD, and HW also acknowledge support from BBSRC Institute Strategic Programme

884 Grants BB/J004324/1 and BB/P013740/1. KMS and DAH are supported by the Mater Foundation,

885 Brisbane, Australia.

886 **Author Contributions**

887 1. Conceptualization: SC JKB DAH PD NB HW KMS.

888 2. Data curation: JKB SC.

889 3. Formal analysis: SC JKB KMS DAH PD BW NP.

890 4. Funding acquisition: JKB DAH YH.

891 5. Investigation: SC JKB DAH PD KMS.

892 6. Methodology: SC JKB DAH.

893 7. Project administration: JKB DAH YH PC ARRF.

894 8. Resources: JKB DAH.

895 9. Supervision: JKB DAH YH PC ARRF.

896 10. Writing – original draft: SC JKB DAH KMS.

897

898

899

900

901 Bibliography

- 902 Andersson, R. *et al.* (2014) 'An atlas of active enhancers across human cell types and tissues',
903 *Nature*, 507(7493), pp. 455–461. doi: 10.1038/nature12787.
- 904 Bailey, T. L. and Elkan, C. (1994) 'Fitting a mixture model by expectation maximization to discover
905 motifs in biopolymers.', *Proceedings. International Conference on Intelligent Systems for*
906 *Molecular Biology*, 2(2), pp. 28–36. Available at: <http://www.ncbi.nlm.nih.gov/pubmed/7584402>.
- 907 Baillie, J. K. *et al.* (2016) 'Shared activity patterns arising at genetic susceptibility loci reveal
908 underlying genomic and cellular architecture of human disease .', *bioRxiv*, pp. 1–24. doi:
909 10.1101/095349.
- 910 Baillie, J. K. *et al.* (2017) 'Analysis of the human monocyte-derived macrophage transcriptome and
911 response to lipopolysaccharide provides new insights into genetic aetiology of inflammatory
912 bowel disease', *PLoS Genetics*, 13(3), pp. 1–36. doi: 10.1371/journal.pgen.1006641.
- 913 Beaton, A. R. and Krug, R. M. (1981) 'Selected host cell capped RNA fragments prime influenza
914 viral RNA transcription in vivo', *Nucleic Acids Research*, 9(17), pp. 4423–4436. doi:
915 10.1093/nar/9.17.4423.
- 916 Bercovich-Kinori, A. *et al.* (2016) 'A systematic view on influenza induced host shutoff', *eLife*,
917 5(AUGUST), pp. 1–20. doi: 10.7554/eLife.18311.
- 918 Budach, S. and Marsico, A. (2018) 'Pysster: Classification of biological sequences by learning
919 sequence and structure motifs with convolutional neural networks', *Bioinformatics*, 34(17), pp.
920 3035–3037. doi: 10.1093/bioinformatics/bty222.
- 921 Canella, D. *et al.* (2010) 'Defining the RNA polymerase III transcriptome: Genome-wide localization
922 of the RNA polymerase III transcription machinery in human cells', *Genome Research*, 20(6), pp.
923 710–721. doi: 10.1101/gr.101337.109.
- 924 Chang, J. T. and Nevins, J. R. (2006) 'GATHER: A systems approach to interpreting genomic

- 925 signatures', *Bioinformatics*, 22(23), pp. 2926–2933. doi: 10.1093/bioinformatics/btl483.
- 926 Chen, E. Y. *et al.* (2013) 'Enrichr: Interactive and collaborative HTML5 gene list enrichment analysis
927 tool', *BMC Bioinformatics*, 14. doi: 10.1186/1471-2105-14-128.
- 928 Cline, T. D., Beck, D. and Bianchini, E. (2017) 'Influenza virus replication in macrophages: Balancing
929 protection and pathogenesis', *Journal of General Virology*, 98(10), pp. 2401–2412. doi:
930 10.1099/jgv.0.000922.
- 931 Everitt, A. R. *et al.* (2012) 'IFITM3 restricts the morbidity and mortality associated with influenza.',
932 *Nature*, 484(7395), pp. 519–23. doi: 10.1038/nature10921.
- 933 Fairfax, B. P. *et al.* (2014) 'Innate immune activity conditions the effect of regulatory variants upon
934 monocyte gene expression', *Science*, 343(6175). doi: 10.1126/science.1246949.
- 935 Forrest, A. R. R. *et al.* (2014) 'A promoter-level mammalian expression atlas.', *Nature*. Nature
936 Publishing Group, 507(7493), pp. 462–70. doi: 10.1038/nature13182.
- 937 Freeman, T. C. *et al.* (2007) 'Construction, visualisation, and clustering of transcription networks
938 from microarray expression data', *PLoS Computational Biology*, 3(10), pp. 2032–2042. doi:
939 10.1371/journal.pcbi.0030206.
- 940 Friesenhagen, J. *et al.* (2012) 'Highly pathogenic avian influenza viruses inhibit effective immune
941 responses of human blood-derived macrophages', *Journal of Leukocyte Biology*, 92(1), pp. 11–20.
942 doi: 10.1189/jlb.0911479.
- 943 Geerts-Dimitriadou, C., Goldbach, R. and Kormelink, R. (2011) 'Preferential use of RNA leader
944 sequences during influenza A transcription initiation in vivo', *Virology*. Elsevier Inc., 409(1), pp. 27–
945 32. doi: 10.1016/j.virol.2010.09.006.
- 946 Gizzi, A. S. *et al.* (2018) 'A naturally occurring antiviral ribonucleotide encoded by the human
947 genome', *Nature*. Springer US, 558(7711), pp. 610–614. doi: 10.1038/s41586-018-0238-4.
- 948 Gnirß, K. *et al.* (2015) 'Tetherin Sensitivity of Influenza A Viruses Is Strain Specific: Role of
949 Hemagglutinin and Neuraminidase', *Journal of Virology*, 89(18), pp. 9178–9188. doi:

- 950 10.1128/JVI.00615-15.
- 951 Gu, W., Gallagher, Glen R, *et al.* (2015) 'Influenza A virus preferentially snatches noncoding RNA
952 caps.', *RNA (New York, N.Y.)*, 21(12), pp. 2067–75. doi: 10.1261/rna.054221.115.
- 953 Gu, W., Gallagher, Glen R., *et al.* (2015) 'Influenza A virus preferentially snatches noncoding RNA
954 caps', *Rna*, 21(12), pp. 2067–2075. doi: 10.1261/rna.054221.115.
- 955 Haye, K. *et al.* (2009) 'The NS1 Protein of a Human Influenza Virus Inhibits Type I Interferon
956 Production and the Induction of Antiviral Responses in Primary Human Dendritic and Respiratory
957 Epithelial Cells', *Journal of Virology*, 83(13), pp. 6849–6862. doi: 10.1128/JVI.02323-08.
- 958 He, Y. *et al.* (2010) 'Influenza A Virus Replication Induces Cell Cycle Arrest in G0/G1 Phase', *Journal
959 of Virology*, 84(24), pp. 12832–12840. doi: 10.1128/JVI.01216-10.
- 960 Hoeve, M. A. *et al.* (2012) 'Influenza virus A infection of human monocyte and macrophage
961 subpopulations reveals increased susceptibility associated with cell differentiation', *PLoS ONE*,
962 7(1). doi: 10.1371/journal.pone.0029443.
- 963 Horby, P. *et al.* (2012) 'The role of host genetics in susceptibility to influenza: A systematic review',
964 *PLoS ONE*, 7(3), pp. 1–9. doi: 10.1371/journal.pone.0033180.
- 965 <http://fantom.gsc.riken.jp/zenbu/> (no date) Consortium, FANTOM 5.
- 966 Hume, D. A. and Freeman, T. C. (2014) 'Transcriptomic analysis of mononuclear phagocyte
967 differentiation and activation.', *Immunological reviews*, 262(1), pp. 74–84. doi:
968 10.1111/imr.12211.
- 969 Irvine, K. M. *et al.* (2009) 'Colony-stimulating factor-1 (CSF-1) delivers a proatherogenic signal to
970 human macrophages.', *Journal of leukocyte biology*, 85(2), pp. 278–288. doi: 10.1189/jlb.0808497.
- 971 Jia, D. *et al.* (2010) 'Influenza Virus Non-Structural Protein 1 (NS1) Disrupts Interferon Signaling',
972 *PLoS ONE*, 5(11), p. e13927. doi: 10.1371/journal.pone.0013927.
- 973 Kanamori-katayama, M. *et al.* (2011) 'Unamplified cap analysis of gene expression on a single-
974 molecule sequencer', *Cold Spring Harbor Genome*, pp. 1150–1159. doi:

- 975 10.1101/gr.115469.110.enough.
- 976 Klinkhammer, J. *et al.* (2018) 'IFN- λ prevents influenza virus spread from the upper airways to the
- 977 lungs and limits virus transmission', *eLife*, 7, p. e33354. doi: 10.7554/eLife.33354.
- 978 Koppstein, D., Ashour, J. and Bartel, D. P. (2015) 'Sequencing the cap-snatching repertoire of H1N1
- 979 influenza provides insight into the mechanism of viral transcription initiation', *Nucleic Acids*
- 980 *Research*, 43(10), pp. 1–13. doi: 10.1093/nar/gkv333.
- 981 Koppstein, David, Ashour, J. and Bartel, D. P. (2015) 'Sequencing the cap-snatching repertoire of
- 982 H1N1 influenza provides insight into the mechanism of viral transcription initiation', *Nucleic Acids*
- 983 *Research*, 43(10), pp. 5052–5064. doi: 10.1093/nar/gkv333.
- 984 Kuleshov, M. V. *et al.* (2016) 'Enrichr: a comprehensive gene set enrichment analysis web server
- 985 2016 update', *Nucleic acids research*, 44(W1), pp. W90–W97. doi: 10.1093/nar/gkw377.
- 986 Lamb, R. A., Lai, C. J. and Choppin, P. W. (1981) 'Sequences of mRNAs derived from genome RNA
- 987 segment 7 of influenza virus: colinear and interrupted mRNAs code for overlapping proteins.',
- 988 *Proceedings of the National Academy of Sciences of the United States of America*, 78(7), pp. 4170–
- 989 4. doi: 10.1073/pnas.78.7.4170.
- 990 Lee, M. N. *et al.* (2014) 'Common Genetic Variants Modulate Pathogen-Sensing Responses in
- 991 Human Dendritic Cells', *Science*, 343(6175), pp. 1246980–1246980. doi: 10.1126/science.1246980.
- 992 Lee, S. M. Y. *et al.* (2009) 'Systems-level comparison of host-responses elicited by avian H5N1 and
- 993 seasonal H1N1 influenza viruses in primary human macrophages', *PLoS ONE*, 4(12). doi:
- 994 10.1371/journal.pone.0008072.
- 995 McCauley, J. W. and Mahy, B. W. (1983) 'Structure and function of the influenza virus genome.',
- 996 *The Biochemical journal*, 211(2), pp. 281–94. doi: 10.1042/bj2110281.
- 997 Monteerarat, Y. *et al.* (2010) 'Induction of TNF- α in human macrophages by avian and human
- 998 influenza viruses', *Archives of Virology*, 155(8), pp. 1273–1279. doi: 10.1007/s00705-010-0716-y.
- 999 Morita, E. *et al.* (2007) 'Identification of Human MVB12 Proteins as ESCRT-I Subunits that Function

- 1000 in HIV Budding', *Cell Host and Microbe*, 2(1), pp. 41–53. doi: 10.1016/j.chom.2007.06.003.
- 1001 Morris, D. E., Cleary, D. W. and Clarke, S. C. (2017) 'Secondary bacterial infections associated with
1002 influenza pandemics', *Frontiers in Microbiology*, 8(JUN), pp. 1–17. doi: 10.3389/fmicb.2017.01041.
- 1003 Nicol, M. Q. and Dutia, B. M. (2014) 'The role of macrophages in influenza A virus infection',
1004 *Future Virology*, 9(9), pp. 847–862. doi: 10.2217/fvl.14.65.
- 1005 Nyman, T. a *et al.* (2000) 'Proteome analysis reveals ubiquitin-conjugating enzymes to be a new
1006 family of interferon-alpha-regulated genes.', *European journal of biochemistry / FEBS*, 267(13), pp.
1007 4011–9. Available at: <http://www.ncbi.nlm.nih.gov/pubmed/10866800>.
- 1008 Ohman, T. *et al.* (2009) 'Actin and RIG-I/MAVS Signaling Components Translocate to Mitochondria
1009 upon Influenza A Virus Infection of Human Primary Macrophages', *The Journal of Immunology*,
1010 182(9), pp. 5682–5692. doi: 10.4049/jimmunol.0803093.
- 1011 Perez-Cidoncha, M. *et al.* (2014) 'An Unbiased Genetic Screen Reveals the Polygenic Nature of the
1012 Influenza Virus Anti-Interferon Response', *Journal of Virology*, 88(9), pp. 4632–4646. doi:
1013 10.1128/JVI.00014-14.
- 1014 Perrone, L. A. *et al.* (2008) 'H5N1 and 1918 pandemic influenza virus infection results in early and
1015 excessive infiltration of macrophages and neutrophils in the lungs of mice', *PLoS Pathogens*, 4(8).
1016 doi: 10.1371/journal.ppat.1000115.
- 1017 Plotch, S. J. *et al.* (1981) 'A unique cap(m7GpppXm)-dependent influenza virion endonuclease
1018 cleaves capped RNAs to generate the primers that initiate viral RNA transcription', *Cell*, 23(3), pp.
1019 847–858. doi: 10.1016/0092-8674(81)90449-9.
- 1020 Ramilo, O. *et al.* (2018) 'Gene expression patterns in blood leukocytes discriminate patients with
1021 acute infections', 109(5), pp. 1–2. doi: 10.1182/blood-2006-02-002477.The.
- 1022 Rao, P., Yuan, W. and Krug, R. M. (2003) 'Crucial role of CA cleavage sites in the cap-snatching
1023 mechanism for initiating viral mRNA synthesis', *EMBO Journal*, 22(5), pp. 1188–1198. doi:
1024 10.1093/emboj/cdg109.

- 1025 van Riel, D. *et al.* (2011) 'Highly pathogenic avian influenza virus H5N1 infects alveolar
1026 macrophages without virus production or excessive TNF-alpha induction', *PLoS Pathogens*, 7(6),
1027 pp. 4–11. doi: 10.1371/journal.ppat.1002099.
- 1028 Van Riel, D. *et al.* (2007) 'Human and avian influenza viruses target different cells in the lower
1029 respiratory tract of humans and other mammals', *American Journal of Pathology*, 171(4), pp.
1030 1215–1223. doi: 10.2353/ajpath.2007.070248.
- 1031 Robinson, M. D., McCarthy, D. J. and Smyth, G. K. (2009) 'edgeR: A Bioconductor package for
1032 differential expression analysis of digital gene expression data', *Bioinformatics*, 26(1), pp. 139–
1033 140. doi: 10.1093/bioinformatics/btp616.
- 1034 Sergushichev, A. (2016) 'An algorithm for fast preranked gene set enrichment analysis using
1035 cumulative statistic calculation', *bioRxiv*, p. 60012. doi: 10.1101/060012.
- 1036 Short, K. R. *et al.* (2017) 'Proinflammatory Cytokine Responses in Extra-Respiratory Tissues during
1037 Severe Influenza', *Journal of Infectious Diseases*, 216(7), pp. 829–833. doi: 10.1093/infdis/jix281.
- 1038 Sikora, D. *et al.* (2014) 'Deep sequencing reveals the eight facets of the influenza
1039 A/HongKong/1/1968 (H3N2) virus cap-snatching process.', *Scientific reports*. doi:
1040 10.1038/srep06181.
- 1041 Sikora, D. *et al.* (2017) 'Influenza A virus cap-snatches host RNAs based on their abundance early
1042 after infection', *Virology*. Elsevier Inc., 509(June), pp. 167–177. doi: 10.1016/j.virol.2017.06.020.
- 1043 Singh, R. and Reddy, R. (2006) 'Gamma-monomethyl phosphate: a cap structure in spliceosomal
1044 U6 small nuclear RNA.', *Proceedings of the National Academy of Sciences*, 86(21), pp. 8280–8283.
1045 doi: 10.1073/pnas.86.21.8280.
- 1046 Söderholm, S. *et al.* (2016) 'Phosphoproteomics to Characterize Host Response During Influenza A
1047 Virus Infection of Human Macrophages', *Molecular & Cellular Proteomics*, 15(10), pp. 3203–3219.
1048 doi: 10.1074/mcp.M116.057984.
- 1049 Stasakova, J. *et al.* (2005) 'Influenza A mutant viruses with altered NS1 protein function provoke

- 1050 caspase-1 activation in primary human macrophages, resulting in fast apoptosis and release of
1051 high levels of interleukins 1 β and 18', *Journal of General Virology*, 86(1), pp. 185–195. doi:
1052 10.1099/vir.0.80422-0.
- 1053 Takahashi, H. *et al.* (2012) '5' end-centered expression profiling using cap-analysis gene expression
1054 and next-generation sequencing. TL - 7', *Nature protocols*. Nature Publishing Group, 7 VN-re(3),
1055 pp. 542–561. doi: 10.1038/nprot.2012.005.
- 1056 Teijaro, J. R. (2014) 'The Role of Cytokine Responses During Influenza Virus Pathogenesis and
1057 Potential Therapeutic Options', in *Influenza Pathogenesis and Control - Volume II*, pp. 3–22.
- 1058 Thakar, J. *et al.* (2013) 'Overcoming NS1-Mediated Immune Antagonism Involves Both Interferon-
1059 Dependent and Independent Mechanisms', *Journal of Interferon & Cytokine Research*, 33(11), pp.
1060 700–708. doi: 10.1089/jir.2012.0113.
- 1061 De Vlugt, C., Sikora, D. and Pelchat, M. (2018) 'Insight into Influenza: A Virus Cap-Snatching',
1062 *Viruses*, 10(11), p. 641. doi: 10.3390/v10110641.
- 1063 Wang, J. *et al.* (2012) 'Innate immune response of human alveolar macrophages during influenza a
1064 infection', *PLoS ONE*, 7(3). doi: 10.1371/journal.pone.0029879.
- 1065 Wang, W. and Krug, R. M. (1998) 'U6atac snRNA, the highly divergent counterpart of U6 snRNA, is
1066 the specific target that mediates inhibition of AT-AC splicing by the influenza virus NS1 protein.',
1067 *RNA (New York, N.Y.)*, 4(1), pp. 55–64. Available at:
1068 <http://www.pubmedcentral.nih.gov/articlerender.fcgi?artid=1369596&tool=pmcentrez&rendertype=abstract>.
1069
- 1070 Wang, X., Hinson, E. R. and Cresswell, P. (2007) 'The Interferon-Inducible Protein Viperin Inhibits
1071 Influenza Virus Release by Perturbing Lipid Rafts', *Cell Host and Microbe*, 2(2), pp. 96–105. doi:
1072 10.1016/j.chom.2007.06.009.
- 1073 Wei, J. *et al.* (2019) 'Ribosomal Proteins Regulate MHC Class I Peptide Generation for
1074 Immunosurveillance', *Molecular Cell*, pp. 1162–1173. doi: 10.1016/j.molcel.2018.12.020.

1075 WHO (no date) <http://www.who.int/mediacentre/factsheets/fs211/en/>.

1076 Younis, I. *et al.* (2013) 'Minor introns are embedded molecular switches regulated by highly

1077 unstable U6atac snRNA', *eLife*, 2013(2), pp. 1–14. doi: 10.7554/eLife.00780.

1078